SiBone (NASDAQ:SIBN - Get Free Report) insider Michael Pisetsky sold 3,725 shares of the business's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $23.32, for a total transaction of $86,867.00. Following the transaction, the insider owned 160,719 shares in the company, valued at $3,747,967.08. This represents a 2.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SiBone Stock Performance
NASDAQ:SIBN traded up $0.38 during mid-day trading on Wednesday, hitting $23.54. The stock had a trading volume of 1,120,107 shares, compared to its average volume of 644,914. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -75.93 and a beta of 0.64. The company's 50 day simple moving average is $20.56 and its 200 day simple moving average is $16.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.15 and a current ratio of 7.58.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The firm had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. On average, equities research analysts forecast that SiBone will post -0.34 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts recently weighed in on SIBN shares. Truist Financial boosted their target price on SiBone from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, October 14th. TD Cowen raised their price target on SiBone from $20.00 to $23.00 and gave the company a "buy" rating in a report on Tuesday, November 3rd. Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. UBS Group upped their price objective on shares of SiBone from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, November 3rd. Finally, Citigroup reissued a "market outperform" rating on shares of SiBone in a research report on Tuesday, November 3rd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.00.
Check Out Our Latest Report on SIBN
Hedge Funds Weigh In On SiBone
Large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in SiBone by 9.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 483,029 shares of the company's stock worth $9,081,000 after purchasing an additional 41,117 shares during the last quarter. Entropy Technologies LP bought a new stake in SiBone in the 3rd quarter valued at $768,000. Pathstone Holdings LLC acquired a new position in SiBone in the 3rd quarter valued at $346,000. Marshall Wace LLP grew its holdings in SiBone by 1.2% in the 3rd quarter. Marshall Wace LLP now owns 698,416 shares of the company's stock valued at $13,130,000 after buying an additional 8,128 shares in the last quarter. Finally, Royce & Associates LP increased its position in SiBone by 15.7% during the 3rd quarter. Royce & Associates LP now owns 457,088 shares of the company's stock worth $8,593,000 after buying an additional 62,000 shares during the period. Institutional investors own 98.11% of the company's stock.
SiBone Company Profile
(
Get Free Report)
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.